XBI
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
State Street SPDR S&P Biotech ETF
- Nom
- State Street SPDR S&P Biotech ETF
- Secteur
- Financial Services
- Industrie
- Asset Management
- Bourse
- AMEX
- Capitalisation
- $7.8B
- Employés
- —
- PDG
- —
- Site web
- https://www.ssga.com/us/en/intermediary/etfs/spdr-sp-biotech-etf-xbi
- Marché
- AIQBBINBBUSEWZFDLIDV
SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2024-05-08 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
| 2024-05-08 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
| 2024-05-08 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2017-02-23 | David Joyce | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. No liquidity or margin figures stored
Market snapshot
Financial ratios
No ratio data synced.
Key metrics
No metrics data synced.
Employee count
No employee-count data synced.
Peer market caps
Recent news
- 2026-10-05 Better Healthcare ETF: Fidelity''s Broad, Low-Cost FHLC vs. State Street''s XBI Targeting Biotech The Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio and a more diversified portfolio than the State Street SPDR S&P Biotech ETF. The State Street SPDR S&P Biotech ETF experienced a much deeper maximum drawdown over the last five years but outperformed on a 1-year total return basis.
- 2026-10-04 Better State Street Healthcare ETF: XBI''s Biotech Focus vs. XPH Targeting Pharmaceuticals The State Street SPDR S&P Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF carry identical 0.35% expense ratios. The State Street SPDR S&P Pharmaceuticals ETF has historically exhibited significantly lower price volatility and a smaller maximum drawdown than its biotech counterpart.
- 2026-09-29 Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.
- 2026-09-22 VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? VHT offers significantly lower ownership costs, with a 0.09% expense ratio compared to XBI''s 0.35%. XBI provides targeted focus on biotechnology, while VHT offers exposure to the entire healthcare sector.
- 2026-09-05 XBI: Big Pharma Can Keep The 76% Rally Going State Street SPDR S&P Biotech ETF (XBI) is rated Buy, with 8%-14% total return expected over 6-12 months despite a 76% prior-year rally. XBI''s modified equal-weight structure offers broad exposure to over 150 biotech names, benefiting from ongoing M&A and improved capital access. Recent large-cap pharma acquisitions and selective capital flows support XBI''s thesis, though volatility remains high and returns are likely to moderate.
- 2026-09-01 Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc''s (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
- 2026-09-01 Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough Merck-Moderna''s melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
- 2026-08-25 XBI Forecast: $174.79 Tests Biotech ETF Breakout Strength XBI approaches its 2021 high at $174.79 after a bullish flag breakout, setting up a key test between further gains and a potential consolidation.
- 2026-08-24 Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
- 2026-08-20 XBI: Biotech''s Breakthrough Moment Happend This Week (Upgrade) State Street SPDR S&P Biotech ETF (XBI) is upgraded to buy as bullish momentum and reasonable valuation converge amid sector-wide optimism. XBI has surged 34% since March, outperforming XLV and SPY, fueled by M&A activity and positive clinical trial catalysts. Despite high volatility and small-cap risk, XBI''s under-20x earnings multiple and diversified holdings support a constructive outlook.